Cancer Research Prevention Award Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, B. S.
Right arrow Articles by Yee, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, B. S.
Right arrow Articles by Yee, D.
Related Collections
Right arrow Therapeutics and Targets
Right arrow Therapeutics and Targets: Identification, Validation, and Markers
[Cancer Research 65, 10123-10127, November 15, 2005]
© 2005 American Association for Cancer Research

Reviews

Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer

Bradley S. Miller1 and Douglas Yee2

Departments of 1 Pediatrics and 2 Medicine, University of Minnesota, Minneapolis, Minnesota

Requests for reprints: Douglas Yee, University of Minnesota Cancer Center, MMC 806, 420 Delaware Street Southeast, Minneapolis, MN 55455. Phone: 612-626-8487; Fax: 612-626-4842; E-mail: yeexx006{at}umn.edu.

Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Al Sorkhy, R. Craig, B. Market, R. Ard, and L. A. Porter
The Cyclin-dependent Kinase Activator, Spy1A, Is Targeted for Degradation by the Ubiquitin Ligase NEDD4
J. Biol. Chem., January 30, 2009; 284(5): 2617 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Cao, Y. Yu, I. Darko, D. Currier, L. H. Mayeenuddin, X. Wan, C. Khanna, and L. J. Helman
Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody
Cancer Res., October 1, 2008; 68(19): 8039 - 8048.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Tarn, L. Rink, E. Merkel, D. Flieder, H. Pathak, D. Koumbi, J. R. Testa, B. Eisenberg, M. von Mehren, and A. K. Godwin
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
PNAS, June 17, 2008; 105(24): 8387 - 8392.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Piao, Y. Wang, Y. Adachi, H. Yamamoto, R. Li, A. Imsumran, H. Li, T. Maehata, M. Ii, Y. Arimura, et al.
Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas
Mol. Cancer Ther., June 1, 2008; 7(6): 1483 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
Y. Kusada, T. Morizono, A. Matsumoto-Takasaki, K. Sakai, S. Sato, H. Asanuma, A. Takayanagi, and Y. Fujita-Yamaguchi
Construction and Characterization of Single-chain Antibodies Against Human Insulin-like Growth Factor-I Receptor from Hybridomas Producing 1H7 or 3B7 Monoclonal Antibody
J. Biochem., January 1, 2008; 143(1): 9 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Barnes, K. Ohshiro, S. K. Rayala, A. K. El-Naggar, and R. Kumar
Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4291 - 4299.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. M. Wilson and P. Rotwein
Selective Control of Skeletal Muscle Differentiation by Akt1
J. Biol. Chem., February 23, 2007; 282(8): 5106 - 5110.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Tanaka, M. Yamamoto, N. Hashimoto, M. Miyakoshi, S. Tamakawa, M. Yoshie, Y. Tokusashi, K. Yokoyama, Y. Yaginuma, and K. Ogawa
Hypoxia-Independent Overexpression of Hypoxia-Inducible Factor 1{alpha} as an Early Change in Mouse Hepatocarcinogenesis
Cancer Res., December 1, 2006; 66(23): 11263 - 11270.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. M. Wilson and P. Rotwein
Control of MyoD Function during Initiation of Muscle Differentiation by an Autocrine Signaling Pathway Activated by Insulin-like Growth Factor-II
J. Biol. Chem., October 6, 2006; 281(40): 29962 - 29971.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Lu, D. Katsaros, A. Wiley, I. A. Rigault de la Longrais, H. A. Risch, M. Puopolo, and H. Yu
The Relationship of Insulin-Like Growth Factor-II, Insulin-Like Growth Factor Binding Protein-3, and Estrogen Receptor-{alpha} Expression to Disease Progression in Epithelial Ovarian Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1208 - 1214.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.